Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial

Inclusion Criteria: children between 3 years and 12 years 11 months diagnosis of autism spectrum disorder confirmed with the Autism Diagnostic Interview- Revised and the Autism Diagnostic Observation Schedule-2, Brief Observation of Symptoms of Autism, or Childhood Autism Rating Scale at least moderate severity of restricted and repetitive behaviors defined by a Children's Yale-Brown Obsessive Compulsive Scale for Autism Spectrum Disorder score ≥ 11 physical development indicative of prepubescence as defined by criteria for Tanner Stage 1 passes MR safety screening (e.g., no metal in the body) and attempts baseline neuroimaging (MRI or EEG) have stable medication regimens (≥ 30 days) and psychosocial treatments (≥ 60 days) prior to randomization with no anticipated changes during the trial Exclusion Criteria: presence of known genetic abnormalities associated with ASD (e.g. Fragile X) current or life-time diagnosis of severe psychiatric disorder (e.g., schizophrenia) presence of significant medical problems the inability of at least one caregiver to speak and read English to a sufficient level participants taking glutathione agents/prodrugs history of any adverse effects to glutathione agents/prodrugs the inability to drink a sample study compound dissolved in liquid